Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure

Saudi Medical Journal

Volumn 28, Issue 2, 2007, Pages 193-196

  Qureshi, Irfan Z ^a   Abid, Kausar ^b   Ambreen, Fareeha ^a   Qureshi, Abid L ^c  

^a QUAID I AZAM UNIVERSITY   (Pakistan)

^b RIPHAH INTERNATIONAL UNIVERSITY   (Pakistan)

^c Khan Research Labs General Hospital   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; FEFOL VIT; FERRIC HYDROXIDE SUCROSE; FERROUS SULFATE PLUS FOLIC ACID; IRON DERIVATIVE; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; RECOMBINANT ERYTHROPOIETIN; TRIHEMIC H; UNCLASSIFIED DRUG; VALSARTAN;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG POTENTIATION; ERYTHROPOIESIS; FEMALE; HEMATOCRIT; HUMAN; HYPERTENSION; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PAKISTAN; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; HEMATOCRIT; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; RENAL DIALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 34147116887     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Remuzzi G, Rossi EC. Hematological consequences of renal failure. In: Brenner MB, Rector FC, editors. The kidney. Philadelphia: WB Saunders: 1995.
2. Similowski T, Agustí A, MacNee W, Schönhofer B. The potential impact of anemia of chronic disease in COPD. Eur Respir J 2006; 27: 390-396.
3. Graciano ML, Cavagleiri RD, Delle H, Dominguez WV, Dulce EC, Densie MA, et al. Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol 2004; 15: 1805-1815.
4. Albitar S, Genin R, Fen-Chong M, Serveaux M, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in hemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-1210.
5. Iain C, MacDougall. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 1999; 14: 1834-1841.
6. Naito M, Kawashima A, Akiba T, Takanshi M, Nihei H. Effect of an angiotensin II receptor antagonist and angiotensin converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Nephrol 2003; 23: 287-293.
7. Grossmann J, Thuram P, Bachmann T, Weller S, Kachel HG, Schoeppe W, et al. Mechanism of angiotensin converting enzyme inhibitor related anemia in renal transplant recipients. Kidney Int 1996; 50: 973-978.
8. Danovitch GM, Jamgotchian JN, Eggena PH, Paul W, Barette JD, Wilkinson A, et al. Angiotensin converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism. Transplantation 1995; 60: 132-137.
9. Rivalan J, Morin MP, Joyeux V, Le Pogamp P. Post-transplant erythrocytosis treatment with Losartan. J Am Nephrol 1996; 7: 1939.
10. Mrug M, Stopka T, Bruce AJ, Jaroslav FP, Josef TP. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 2000; 100: 2310-2314.
11. Azizi M, Rousseau A, Ezan E, Guyene TT. Acute angiotensin converting enzyme inhibition increases the plasma levels of natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996; 97: 839-844.
12. Marathias KP, Agroyannis B, Mavromoustakos T, Matsoukas J, Vlahokas DV. Hematocrit lowering affects following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem 2004; 4: 483-486.
13. Corvol P, Williams JA, Soubrier F. Peptidyl dipeptidase A: angiotensin 1 converting enzyme. Meth Enzymol 1995; 248: 283-305.
14. Danser AH, Saris JJ, Schuijt MP, Vankats JP. Is there a local renin angiotensin system in the heart? Cardiovasc Res 1999; 44: 252-265.
15. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766-771.
16. Dechow C, Morath C, Peters J, Lehrke I, Waldherr R, Haxsen V, et al. Effects of all-trans retinoic acid on renin-angiotensin system in rats with experimental nephritis. Am J Physiol Renal Physiol 2001; 281: F909-F919.
17. Kamper A, Neilson OJ. Effect of enalapril on hemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest 1990; 50: 611-618.
18. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med 1993; 329: 1456-1462.
19. Walter J. Does captopril decrease the effect of human recombinant erythropoietin in hemodialysis patients? Nephrol Dial Transplant 1993; 8: 1428.
20. Sanchez RA, Gimenez MI, Migliorini M, Giannone C, Romite Z, Weder AB. Erythrocyte sodium-lithium counter transport in on-modulating off-spring and essential hypertensive individuals: response to enalapril. Hypertension 1997; 30: 99-105.
21. Hayashi K, Hasegawa K, Kobayashi S. Effects of angiotensin converting enzyme inhibitors on the treatment of anemia with erythropoietin. Kidney Int 2001; 60: 1910-1916.
22. Macdougall IC. Poor response to erythropoietin: Practical guidelines on investigations and management. Nephrol Dial Transplant 1995; 10: 607-614.
23. Macdougall IC, Gray SJ, Elston O. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-2395.